NuSep to Buy BioInquire | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian bioseparations company NuSep has signed an agreement to buy proteomics software maker BioInquire through a cash, stock, and milestone arrangement worth an expected $3 million or more.

BioInquire, based in Athens, Ga., sells the ProteoIQ software for analysis and identification of protein samples post-processing on a mass spec instrument against large structure and function databases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.